US FDA approves Hikma’s generic version of Novo’s diabetes drug Victoza | Reuters
Excerpt from Reuters: “The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug Victoza, clearing the way for the launch of another copy of the treatment in the country.
Hikma’s branded generic will compete with Teva Pharmaceuticals authorized generic of Victoza in the United States that was launched earlier this year.
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s permission.” Read more.
Systane eye drops recalled for possible fungal contamination, FDA says | NBC News
Excerpt from the NBC News: “Systane brand eye drops were voluntarily recalled because of possible fungal contamination, the Food and Drug Administration said.
One lot of Systane Lubricant Eye Drops Ultra PF was recalled following a consumer complaint “of foreign material observed inside a sealed single-use vial,” the FDA said in a release. It was determined that the material was “fungal in nature.”” Read more.
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices | USA Today
Excerpt from USA Today: “The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs.
The FDA has issued warnings against the off-brand versions, citing safety concerns.” Read more.
Sorry, the comment form is closed at this time.